ResearcherJilin UniversityNo recent work listed
Shuang Liu
Matched on ORCID iD 0009-0005-9951-948X; OpenAlex author ID A5041282750.
Their work
- Papers
- 3 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Collaborators
- 5
2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: 1 paper
Papers 3
- Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer. First author DOI 10.1007/s00280-020-04210-0↗
- Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Co-author DOI 10.18632/oncotarget.17869↗
- Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide… First author DOI 10.3892/or.2017.5580↗
Closest collaborators
The 5 strongest of 5 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Guan Wang · 3 shared papers, 2017–2021
- Paper Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer. DOI 10.1007/s00280-020-04210-0↗
- Paper Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA… DOI 10.3892/or.2017.5580↗
- Paper Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of … DOI 10.18632/oncotarget.17869↗
- Yubin Ge · 2 shared papers, 2017
- Paper Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA… DOI 10.3892/or.2017.5580↗
- Paper Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of … DOI 10.18632/oncotarget.17869↗
- Tingting Wang · 1 shared paper, 2017
- Changwen Ning · 1 shared paper, 2017
- Asfar Sohail Azmi · 1 shared paper, 2017
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.